Telomir Pharmaceuticals (NASDAQ:TELO) Stock Jumps 2.2% – Here’s Why

Telomir Pharmaceuticals, Inc. (NASDAQ:TELO)’s stock price rose 2.2% on Tuesday. The company traded as high as $1.07 and last traded at $1.02. Approximately 54,829 shares changed hands during trading, The stock had previously closed at $0.9985.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on TELO. Maxim Group assumed coverage on shares of Telomir Pharmaceuticals in a research note on Thursday, September 17th. They set a “buy” rating and a $4.00 price target for the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Telomir Pharmaceuticals in a research report on Thursday, October 15th. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $4.00.

Telomir Pharmaceuticals Price Performance

The stock has a market capitalization of $66.32 million, a P/E ratio of -1.06 and a beta of -0.31. The company’s 50-day simple moving average is $1.14 and its 200-day simple moving average is $1.23.

Telomir Pharmaceuticals (NASDAQ:TELO) last announced its quarterly earnings data on Thursday, August 13th. The company reported ($0.79) EPS for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.72).

Hedge Funds Weigh In On Telomir Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. OneDigital Investment Advisors LLC acquired a new stake in shares of Telomir Pharmaceuticals in the second quarter valued at approximately $29,000. Bank of New York Mellon Corp bought a new position in Telomir Pharmaceuticals in the 2nd quarter valued at about $66,000. Finally, BlackRock Inc. bought a new position in Telomir Pharmaceuticals in the 2nd quarter valued at about $359,000.

Telomir Pharmaceuticals Company Profile

Telomir Pharmaceuticals, Inc is a development-stage biotechnology company focused on therapies intended to address age-related diseases and conditions. The company’s research is centered on telomere biology, a field involving the protective DNA sequences at the ends of chromosomes that are associated with cellular aging.

Telomir’s lead investigational product is TELOMIR-1, an orally administered small-molecule compound being developed to promote telomere lengthening and support cellular health.